Kazia Therapeutics Limited Stock News

SYDNEY, Dec. 4, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce positive final data from a phase II clinical study of paxalisib as first line therapy in patients with glioblastoma (NCT03522298).

Kazia Therapeutics Ltd (ASX:KZA, NASDAQ:KZIA), a cancer-focused drug development company based in Sydney, has released final data from its Phase 2 clinical study of the drug paxalisib – a first-li

SYDNEY , Nov. 29, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an oncology-focused drug development company, is pleased to inform stakeholders that the GBM AGILE study in glioblastoma (NCT03970447) has opened at Sunnybrook Health Sciences Centre in Toronto, Ontario . This marks the first Canadian site to open to paxalisib, and the first opportunity for Canadian patients to access the drug. Sunnybrook Health Sciences Centre, under the leadership of principal investigator, Dr James Perry , will join more than two dozen US sites currently recruiting to the paxalisib arm. Three further sites in Canada are presently working through the administrative requirements to open to paxalisib and are expected to do so in coming weeks. Key Points GBM AGILE is a multi-drug platform study, designed to identify promising new therapies for glioblastoma. It is sponsored by the Global Coalition for Adaptive Research (GCAR) and three drug candidates are currently participating: Bayer''s regorafenib, Kazia''s paxalisib, and VAL-083 from Kintara Therapeutics.

Kazia Therapeutics Ltd (ASX:KZA, NASDAQ:KZIA)'s cancer drug, paxalisib, which targets glioblastoma, will now reach patients in Canada through a new study at Sunnybrook Health Sciences Centre in T

Kazia Therapeutics Limited (NASDAQ:KZIA) was the recipient of a large drop in short interest during the month of October. As of October 29th, there was short interest totalling 2,300 shares, a drop of 37.8% from the October 14th total of 3,700 shares. Based on an average trading volume of 26,300 shares, the days-to-cover ratio is []

Pre-open movers U.S. stock futures traded higher in early pre-market trade after closing higher in the prior session. Investors are awaiting earnings results from Tyson Foods, Inc. (NYSE: TSN), Warn

Kazia Therapeutics Ltd (ASX:KZA, NASDAQ:KZIA) has appointed John Friend MD, the former chief medical officer (CMO) at Cellectar Biosciences (NASDAQ:CLRB), Inc as its new CMO.  Dr Friend will be resp

Kazia Therapeutics Ltd (ASX:KZA, NASDAQ:KZIA)'s investigational drug paxalisib is playing a role in PNOC022, a multi-drug phase II study in DIPG and diffuse midline gliomas, that has been initiated at

Kazia Therapeutics Ltd (ASX:KZA, NASDAQ:KZIA) has officially enrolled its first patient in its investigational cancer therapy trial. The oncology-focused drug development company licensed the cancer t

Kazia Therapeutics Ltd (ASX:KZA, NASDAQ:KZIA) has received the nod from two research houses, with the Maxim Group LLC initiating coverage with a ‘buy' recommendation and Edison increasing its valua

Kazia Therapeutics Ltd has received an increased target price share from Edison Group, rising to A$2.83 from A$2.68 a share following the release of interim data for its 30-patient Phase II trial of

SYDNEY, Oct. 6, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be prese

SYDNEY, Sept. 10, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be pres

Kazia Therapeutics Ltd has received full regulatory approval for its planned phase 1 study for EVT801 from L'Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM), the French